- Novo Nordisk A/S NVO Has completed release topline Results from its six ONWARDS Phase 3a clinical trials of once-weekly dosing of insulin icodec in people with diabetes.
- The ONWARDS 5 study found that once-weekly insulin Icodec was non-inferior to once-daily basal insulin in reducing HbA1c. The 52-week open-label study thus met its primary endpoint at the end of the study.
- Novo’s Icodec resulted in a -1.68 percentage point reduction in HbA1c compared to -1.31% for the once-daily control. The study included 1,085 insulin-naïve people with type 2 diabetes. Icodec patients also used an app to control their dosage.
- The news complements the ONWARDS test results is from April.
- In July, the company announced headline results from the phase 3a studies ONWARDS 3 and ONWARDS 4 with insulin icodec once weekly.
- Earlier this month, Novo lost weight worldwide marketing rights to Seeland Pharma A/S‘s ZEAL Diabetes treatment Zegalog and signed a $1.1 billion acquisition Forma Therapeutics Holdings Inc FMTX for his sickle cell drug.
- Novo Nordisk expects to apply for regulatory approval of once-weekly insulin icodec in the US, EU and China in H1 2023.
- Price promotion: NVO shares are up 2.26% to $101.88 on Monday’s latest check.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
